Alto Neuroscience, Inc. (ANRO)
(Delayed Data from NYSE)
$14.86 USD
-0.13 (-0.87%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $14.96 +0.10 (0.67%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANRO 14.86 -0.13(-0.87%)
Will ANRO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ANRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANRO
Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions
ANRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ANRO
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder
Alto Neuroscience completes enrollment in ALTO-100 study
Buy Rating Affirmed for Alto Neuroscience’s Innovative Schizophrenia Treatment ALTO-101
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
Alto Neuroscience initiates Phase 2 study of ALTO-101